Shares of Helix Biopharma Corp. (OTCMKTS:HBPCF – Get Free Report) dropped 55.5% during trading on Monday. The stock traded as low as $0.77 and last traded at $0.77. Approximately 200 shares traded hands during trading, The stock had previously closed at $1.73.
Helix Biopharma Price Performance
The company has a market capitalization of $58.81 million, a price-to-earnings ratio of -19.25 and a beta of 0.18. The stock has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $1.71.
About Helix Biopharma
Helix BioPharma Corp. is a Canadian biotechnology company focused on developing novel therapies for cancer. Its research has centered on targeted treatments intended to address the tumor microenvironment and improve the delivery or effectiveness of anticancer agents.
The company’s principal investigational product has been L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. The treatment is intended to alter the acidic conditions surrounding tumors, which may help create an environment less favorable to cancer-cell growth.
Further Reading
- Five stocks we like better than Helix Biopharma
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
